RT Journal Article
SR Electronic
A1 Powers, Jenny
T1 Immunomodulation of Checkpoints Resets Immune System in NSCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 4
OP 5
DO 10.1177/155989771403001
UL http://mdc.sagepub.com/content/14/3/4.abstract
AB Although advances seemed elusive throughout past years, immunotherapy is beginning to fulfill its promise in the treatment of non—small cell lung cancer (NSCLC). For years, researchers have been intrigued by the notion of trying to enlist the immune system to attack tumors; however, little was actually realized until the mechanisms of immune evasion used by tumor cells were defined and immune regulators of the programmed death and programmed death ligand (PD-1—PD-L1) pathway were recently devised. This article discusses the advent of immunotherapy that was made possible by the development of immune checkpoint inhibitors that target the PD-1—PD-L1 pathway.